Quote this publication Share Print

SKUDEXUM 75 mg/25 mg, dexketoprofen/tramadol, Fixed NSAID-weak opioid combination

PAIN - New medicinal product
Opinions on drugs - Posted on Jul 20 2016

Reason for request


No clinical benefit demonstrated relative to other available analgesics.

  • SKUDEXUM has Marketing Authorisation in the short-term symptomatic treatment of moderate to severe acute pain in adult patients whose pain requires a combination of tramadol and dexketoprofen.
  • Its analgesic superiority relative to each of its constituents administered as a monotherapy was demonstrated in two studies.
  • No comparison with other fixed analgesic combinations is available.


Clinical Benefit



Clinical Added Value

no clinical added value


Therapeutic use


Contact Us

Évaluation des médicaments